Laboratory Testing for Hospitalized Patients on Emicizumab
For hospitalized patients receiving emicizumab, essential laboratory monitoring should include: complete blood count (CBC) with differential, comprehensive metabolic panel (CMP) including renal and hepatic function tests, and specialized coagulation testing using chromogenic FVIII assays with bovine reagents (not standard aPTT-based tests) when FVIII measurement or inhibitor detection is needed.
Core Laboratory Panel
Baseline and Routine Monitoring
CBC with differential and platelet count 1
- Monitor for thrombocytopenia if thrombotic microangiopathy (TMA) is suspected
- Essential for detecting hematologic complications
Renal function tests (BUN, creatinine) 1
- Critical for TMA surveillance, particularly if activated prothrombin complex concentrate (aPCC) has been used
- Decreased urination is a warning sign requiring immediate assessment
Hepatic function tests (ALT, AST, total bilirubin) 1
- Monitor for TMA-related organ injury
- Yellowing of skin/eyes indicates potential TMA
Electrolytes and comprehensive metabolic panel 1
- Standard hospitalized patient monitoring
- Helps assess overall organ function
Specialized Coagulation Testing
Critical Caveat About Standard Tests
Emicizumab interferes with all aPTT-based coagulation tests, rendering them unreliable and potentially dangerous for clinical decision-making 1, 2, 3. Standard tests that should NOT be used include:
- Activated partial thromboplastin time (aPTT)
- One-stage aPTT-based FVIII assays
- Standard Bethesda assays for FVIII inhibitors
- Activated clotting time (ACT)
Appropriate Coagulation Monitoring
When FVIII measurement is needed (e.g., if FVIII is administered for breakthrough bleeding):
- Chromogenic FVIII assay using bovine reagents 2, 4, 5
- This is the only reliable method to measure FVIII activity in the presence of emicizumab
- Human-based chromogenic assays will be falsely elevated
When inhibitor testing is required:
- Modified chromogenic assay with bovine reagents 5, 6
- Standard Bethesda assays will give false-negative results in emicizumab-treated patients
- Essential for detecting new inhibitor development, particularly in previously untreated patients (PUPs) or young children 7
When emicizumab level measurement is needed (suspected loss of efficacy, increased breakthrough bleeding):
- Modified one-stage assay (mOSA) with higher dilution and emicizumab-specific calibration 8
- Emicizumab-calibrated chromogenic assay 8
- Liquid chromatography-tandem mass spectrometry (if available) 8
Clinical Scenarios Requiring Enhanced Monitoring
If aPCC Has Been Used (>100 U/kg cumulative dose)
Monitor aggressively for TMA and thromboembolism 1:
- Serial CBC (watch for hemolytic anemia, thrombocytopenia)
- Daily renal function
- LDH and haptoglobin (for hemolysis)
- Urinalysis
- Clinical assessment for confusion, weakness, swelling, chest pain, shortness of breath
Pre-Surgical or Pre-Procedure
- Baseline CBC, CMP, hepatic panel
- If FVIII will be administered perioperatively, ensure chromogenic FVIII assay with bovine reagents is available 6
- Do NOT rely on aPTT for surgical hemostasis assessment 2, 3
Breakthrough Bleeding Episodes
- CBC to assess for acute blood loss
- If FVIII or bypassing agents are needed, use appropriate monitoring as above
- Consider emicizumab level if multiple breakthrough bleeds suggest loss of efficacy 8, 7
Anti-Drug Antibody (ADA) Testing
If clinical loss of efficacy is suspected (increased breakthrough bleeding):
- Test for neutralizing anti-emicizumab antibodies 1, 8
- This is uncommon (<1% incidence) but requires prompt recognition
- May necessitate treatment change
Key Pitfalls to Avoid
Never use standard aPTT or aPTT-based assays to guide clinical decisions in emicizumab patients—they will be falsely shortened and misleading 1, 2, 3
Do not assume normal hemostasis based on normalized aPTT—emicizumab normalizes aPTT but does not provide complete hemostatic correction 4
Avoid cumulative aPCC doses >100 U/kg over 24 hours due to high risk of TMA and thrombosis—if this threshold is approached or exceeded, intensify monitoring immediately 1
Ensure laboratory is aware the patient is on emicizumab before any coagulation testing to prevent misinterpretation 1, 2
Maintain inhibitor surveillance in young children and PUPs even while on emicizumab prophylaxis, as inhibitors can still develop with FVIII exposure and require changes in bleed management 7